Live Chat

Los Contratos por diferencia («CFD») son instrumentos complejos que comportan un riesgo elevado de pérdidas rápidas debido al apalancamiento. El 74% de las cuentas de inversores particulares pierde dinero al operar CFD con este proveedor. Debe considerar si comprende el funcionamiento de los CFD y si puede permitirse asumir un riesgo elevado de perder su dinero.

Close

Opere BioNTech BNTX

Vender
 Comprar

BioNTech gráfico en tiempo real

5m 15m 30m 1h 4h 1d 1w

Fundamentales del instrumento

Weekly Search
Weekly
Daily
Fecha Cerrar Cambio Cambio del % Apertura Alto Bajo

Últimas noticias

Nvidia Blackwell AI Chips
Markets.com Support Team 2024 Nov 14, 16:00

Adelanto semanal: El rally tecnológico dependerá de los resultados de Nvidia

Forex Índices
Markets.com Support Team 2024 Nov 07, 16:00

Adelanto semanal: «Trump Trade», datos de inflación, resultados de Disney

Forex Índices
US Election 2024, Harris vs Trump
Markets.com Support Team 2024 Oct 31, 16:00

Adelanto semanal: Trump vs Harris - Enfrentamiento electoral en EE. UU.

Forex Índices
Big Tech, Apple, Meta, Microsoft, Amazon & Alphabet
Markets.com Support Team 2024 Oct 24, 16:00

Adelanto semanal:  Apple encabeza las ganancias de las grandes tecnológicas, presupuesto del Reino Unido y nóminas no agrícolas

Forex Índices
Time for Tesla earnings
Markets.com Support Team 2024 Oct 17, 16:00

Adelanto semanal:  Hora de los resultados de Tesla

Forex Índices
ECB set to cut rates for the third time this year
Markets.com Support Team 2024 Oct 10, 16:00

Adelanto semanal:  El BCE se prepara para recortar las tasas mientras arranca la temporada de ganancias en Wall Street

Forex Índices
New Zealand rate cut likely, FOMC and RBA minutes out
Markets.com Support Team 2024 Oct 05, 16:00

Adelanto semanal: Publicación de las actas del FOMC, probabilidad de más bajadas de tipos en Nueva Zelanda

Forex Índices
Markets eye Powell speech, nonfarm payrolls for clues on future cuts
Markets.com Support Team 2024 Sep 26, 16:00

Adelanto semanal: Los mercados buscarán pistas de recortes de tasas en noviembre en los comentarios de Powell y las cifras de empleo

Forex Índices

Información

Spread

1.0525

Spread (%)

1.0364 %

Apalancamiento

1:5

Interés a un día (Compra)

-0.0597 %

Interés a un día (Venta)

-0.0292 %

Divisa

USD

Horarios de los mercados

Markets closed

Jueves

14:31 - 20:59

Lunes

14:31-20:59

Martes

14:31-20:59

Miércoles

14:31-20:59

Viernes

14:31-20:59

Análisis y estadísticas

Apertura

---

Cierre anterior

---

Máximo/mínimo de 52 semanas

--- – ---

Capitalización de mercado

25508335616

Acciones en circulación

239740000

Fecha de ganancias (próxima)

0000-00-00

Rentabilidad por div. 

2022-06-17

Fecha exdividendo

2022-06-02

Tasa de dividendo anual anticipado

0

Rendimiento de dividendo anual anticipado

0

GPA

-2.05

Conoce más sobre este instrumento

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

Instrumentos relacionados

Activo
Vender
Comprar
Cambio del %

Opere ahora

Opere ahora

Opere ahora

Opere ahora
Instrumentos relacionados
Trustpilot
Live Chat